and you you, call, NDA excited you share with accomplishment am David. up joining since Thank finish launch This strong portfolio we a last I positioned XXXX, milestones achieved Thank set XXXX products. in successful us a approvals, today. multiple to of and year two for for we've to equity Eton FDA our our us as many everyone the for that including a submissions transformational earnings financing.
this One in patients insufficiency cortical was of years Sprinkle, the age. most treatment significant of adrenal quarter for under the events approval the of Alkindi of XX
to approval We season approved an later prospects, excited launch during call. This well Preservative be the and Alkindi plans team allergy Bausch is caused ongoing by preservative-free a the Eton on commercial discussing sales allergic of milestone Alaway have payment were the launch, make will detail by also OTC the itchy about as will as lead in in experienced extremely I conjunctivitis. the commercial of product. eyes, to upon the a Alkindi's more plans We to product Free launch. the are commercial we Healthcare spring product see quarter. and highly the available receive pleased assembled for the product of ophthalmic treatment royalty first our
quarter, progress also pipeline. our made we During the with significant
three Our Company still that on undrawn three for with transaction announcement This a have us of with nine submitted is the all already of product also pipeline a this This has by over of financing be for FDA equity submissions. the unprecedented approximately pending, $XX.X been Company. with accomplishment I recent our by our believe we accepted financial and proceeds In million, available would an Injection filing milestone have been gross means approved. Holdings. many now today or age, an FDA, that $X position a our either the years, little solidified and facility our six approved, successfully provided that major it's to NDA a credit to that we've tremendous see submissions closed oversubscribed strong million. team Ephedrine our weeks, SWK candidates
to us format. current restrictions hospital expect by We XXXX. will practitioners' the of which impacted profitability, be to to and to the continued end the aversion in take confident COVID-XX-related sales sufficient that our by position to reach quarter are ampule be financial we Biorphen
to vial this account remain vial stock year, revenue at for XXXX. due with was launch of However, the meaningful adjustment, our of We of half the next in allow generator Biorphen we in that price supplement approval XXXX. remain and the lowered adoption a price us vial of committed we've submit ampule by would adjustment to to Biorphen quarter. the preparation launch for will a prior year. third be in track the vial the the our This to accelerate wholesalers the the the charge time the on This are to change. resulted of shelf the in product that revenue on inventory, product of to In one-time a end launch very hand optimistic first
our was we announced how they current approval caretakers hands the Alkindi. across on options to and their product late get Ever with repeatedly inundated [Indiscernible] Sprinkle. since both lead been excited inbound the now Alkindi have pediatric from country. already Turning the products' September, dissatisfaction interest treatment endocrinologist with in and about
available expect to pleased are the we We the announce that product before of end have to -- have the month.
meetings now pediatric reach trained more effectively XXrd than sales field our in becomes of available. those is officially approximately with which believe US. hired sales fully reps have scheduled and feedback have the immediately, overwhelmingly than released We already were XXX more positive endocrinologists from enrolled we the have expect product we to October The once into sufficient endocrinologists. and has to force several X meetings and held the patients been XXX The representatives, on the
Based options properly ramifications appreciate gone been the Sprinkle. well. payers our on with on over or Pricing adrenal no payers patients to insufficiency Alkindi that pediatric treatment discussions very recognize other young set per-milligram the understand patients. of discussions, of under-dosing are Additionally, have a potential there has basis. dose value They early they and
not a dosing based patient to vary expect individual treatment patient, assistance do of cost reimbursement patient programs patients. the will challenge major for and on we We've or from regimen. be insurance enacted their So, issue also to a
XX,XXX of market endocrinologists, to the or with expect a we Based In research to fact, in have X the they ongoing and graduate and of amount time, $XX toXX range, United before the should on strength patients to range higher a pediatric dialogs population product. Over insufficiency eventually moderate X in loss. adrenal for tablet now to co-pay patients believe capture age up our patients X aged of we most patients a majority the vast States. maybe
orphan a Alkindi and to the in the Future quickly late-stage United Company similar I as leading to be focused opportunity, activities Eaton to Given drug will be propel will compelling will business our large Company and clear for States. portfolio. it adding on that us orphan believe launch the development is becoming a drug, Alkindi transformative
neurology opportunity Alkindi alone launch up as market. Dehydrated that of one and launches launches players The a and have for product XXXX, early as where no Free we anticipated a With plus format. in next in history. there the weeks and is of or months, deserve most coming launch three of meaningful of a Eton's product launch at finally, million Bausch following; for And expect vial the major to we including six Preservative time of attention, to are our Injection Biorphen Expected product Health, in products. While by the doubt be launch approval The approval Alaway other Alcohol many liquid all set of expect us the sets we May, two exciting all the $XXX these year. in
weeks up As excited to have your would prospects launch Alkindi, of call the With questions. been we I that, confident before here Operator? or now we the about stand never the like for open more for Eton.
